The Axxent® Electronic Brachytherapy System® utilizes a miniaturized high dose rate X-ray source to apply radiation directly to the cancerous tumor bed. It was cleared for marketing by the FDA in December 2005. Unlike traditional high dose rate brachytherapy technologies, this form of brachytherapy is claimed not to require radioactive isotopes, heavy shielding, or major capital equipment. A number of posters and presentations, most of it in breast cancer, presented this new technology over the past three years. Five research studies were accepted for presentation at the 2008 World Congress of Brachytherapy hosted by the American Brachytherapy Society (ABS). One of them was about the use of the Axxent System for treatment of cervical cancer, subsequently published, and another about endometrial cancer.
Dickler A, Kirk MC, Griem K, Dowlatshahi K, Francescatti D, Abrams RA. A dosimetric comparison of MammoSite high-dose-rate brachytherapy and Xoft Axxent electronic brachytherapy. Brachytherapy 2007;6:164-168.
K. Huber, J. Hiatt, M. Puthawala, D. Wazer Dose modeling of the Xoft electronic brachytherapy source for tandem and ovoid applications in patients with cervical cancer
Brachytherapy, Volume 7, Issue 2, Pages 155-155
TEC, Accelerated Partial Breast Irradiation as Sole Radiotherapy After Breast-Conserving Surgery for Early Stage Breast Cancer
Assessment Program Volume 22, No. 4 September 2007